Market Cap 2.71B
Revenue (ttm) 63.72M
Net Income (ttm) -193.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -303.69%
Debt to Equity Ratio 0.27
Volume 922,300
Avg Vol 3,038,282
Day's Range N/A - N/A
Shares Out 213.05M
Stochastic %K 14%
Beta 0.96
Analysts Strong Sell
Price Target $23.58

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Fax: 781 275 7562
Address:
15 Crosby Drive, Bedford, United States
BillionerOfKing
BillionerOfKing Dec. 25 at 3:44 AM
$OCUL Current Stock Price: $12.72 Contracts to trade: $10 OCUL Jan 16 2026 Call Entry: $2.85 Exit: $3.75 ROI: 32% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 10:17 AM
Enter: $OCUL Calls Strike Price: $14 Expiry Date: JAN 16 2026 Buy in Price: $0.65 - $0.68 Sell Price: $1.13 Profit : +74% (Turn every $1 into $1.74) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Tmoney85285
Tmoney85285 Dec. 23 at 3:09 PM
$OCUL hope you guys didn't fall for the bull trap yesterday! btw, since dugel's 8K, EYPT has started to quickly close the gap in MC between the companies...market doesn't buy the tactics!
1 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Dec. 23 at 2:53 AM
$OCUL Take some time holiday season to thank the lord or what ever deity that you hold dear to you. Please consider helping those that need help. This year I chose https://donate.shrinerschildrens.org/campaign/750024/donate May you all receive many blessings in the coming New Year 🙏❤️
1 · Reply
dixiebull
dixiebull Dec. 22 at 9:39 PM
$TE slow push to 7.38 afterhours, see if 7.50 breaks for 8, want 7.25 to hold $AMRX FDA approval pushed to 13.12, see if 12.75 holds on a dip for 13.50 and 15 $OCUL testing 13 here, if 13 breaks it can get 13.50/14 $CETX afterhours run to 3.77, see if 3.50 holds for 4 and 4.50 to 5 $IONQ hit 55.60 with a strong market, see if 53.50 holds for 56.50 and 58
0 · Reply
Harvo
Harvo Dec. 22 at 8:51 PM
$OCUL lol
1 · Reply
Jjarnold44
Jjarnold44 Dec. 22 at 7:58 PM
0 · Reply
Fishfearme72
Fishfearme72 Dec. 22 at 7:18 PM
$OCUL Green?
0 · Reply
ils85
ils85 Dec. 22 at 5:37 PM
$OCUL loading
0 · Reply
SmokenTuna
SmokenTuna Dec. 22 at 5:04 PM
$OCUL it’s all green and xbi is flying. Anytime now.
0 · Reply
Latest News on OCUL
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Oct 1, 2025, 4:22 AM EDT - 3 months ago

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript


Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 10:16 AM EST - 10 months ago

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript


Ocular Is Now Thoroughly Derisked

Dec 30, 2024, 12:16 PM EST - 1 year ago

Ocular Is Now Thoroughly Derisked


Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results


Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024


Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Reports First Quarter 2024 Results


BillionerOfKing
BillionerOfKing Dec. 25 at 3:44 AM
$OCUL Current Stock Price: $12.72 Contracts to trade: $10 OCUL Jan 16 2026 Call Entry: $2.85 Exit: $3.75 ROI: 32% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 10:17 AM
Enter: $OCUL Calls Strike Price: $14 Expiry Date: JAN 16 2026 Buy in Price: $0.65 - $0.68 Sell Price: $1.13 Profit : +74% (Turn every $1 into $1.74) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Tmoney85285
Tmoney85285 Dec. 23 at 3:09 PM
$OCUL hope you guys didn't fall for the bull trap yesterday! btw, since dugel's 8K, EYPT has started to quickly close the gap in MC between the companies...market doesn't buy the tactics!
1 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Dec. 23 at 2:53 AM
$OCUL Take some time holiday season to thank the lord or what ever deity that you hold dear to you. Please consider helping those that need help. This year I chose https://donate.shrinerschildrens.org/campaign/750024/donate May you all receive many blessings in the coming New Year 🙏❤️
1 · Reply
dixiebull
dixiebull Dec. 22 at 9:39 PM
$TE slow push to 7.38 afterhours, see if 7.50 breaks for 8, want 7.25 to hold $AMRX FDA approval pushed to 13.12, see if 12.75 holds on a dip for 13.50 and 15 $OCUL testing 13 here, if 13 breaks it can get 13.50/14 $CETX afterhours run to 3.77, see if 3.50 holds for 4 and 4.50 to 5 $IONQ hit 55.60 with a strong market, see if 53.50 holds for 56.50 and 58
0 · Reply
Harvo
Harvo Dec. 22 at 8:51 PM
$OCUL lol
1 · Reply
Jjarnold44
Jjarnold44 Dec. 22 at 7:58 PM
0 · Reply
Fishfearme72
Fishfearme72 Dec. 22 at 7:18 PM
$OCUL Green?
0 · Reply
ils85
ils85 Dec. 22 at 5:37 PM
$OCUL loading
0 · Reply
SmokenTuna
SmokenTuna Dec. 22 at 5:04 PM
$OCUL it’s all green and xbi is flying. Anytime now.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 22 at 4:18 PM
Enter: $OCUL Calls Strike Price: $14 Expiry Date: JAN 16 2026 Buy in Price: $0.75 - $0.85 Sell Price: $1.66 Profit : +121% (Turn every $1 into $2.21) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Tmoney85285
Tmoney85285 Dec. 22 at 3:08 PM
$OCUL i see that moron fairvalue10 blocked me, who is spouting off that OCUL is going to get bought because of the 8K's they issued. spoiler- not getting bought. shorts are piling in as the short position rockets up here! stock is priced for perfection, you're better off going long with $EYPT and shorting $OCUL until the valuation gap is closer! keep the red days coming boys!
1 · Reply
Tmoney85285
Tmoney85285 Dec. 22 at 2:43 PM
$OCUL can't wait to see the excuses today when this drops another 40 cents! durrr triple witching durrr opex durrrr options!! get a clue, stock is in the middle of a free fall.
1 · Reply
SmokenTuna
SmokenTuna Dec. 22 at 11:24 AM
$OCUL https://finance.yahoo.com/video/2026-outlook-small-cap-biotechs-110000111.html
0 · Reply
1iquid
1iquid Dec. 22 at 3:45 AM
💎 Liquid® Live Actionable Trade Asset: $OCUL Contracts: $OCUL January 15, 2027 $15 Calls Scale in: $4.37- $5.33 Scale out: $16.97-$29.10 Profit Potential : 263% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
Mike826_1999
Mike826_1999 Dec. 22 at 1:37 AM
$OCUL I’m looking to corner the market in wet AMD by owning $OTLK and OCUL. Both have promising drugs. OCUL (AXPAXLI) is in phase 3, not approved in EU or UK, it apparently requires fewer injections than Lytenava. OTLK (LYTENAVA) is approved in EU and UK, and has a DEC 31 pdufa date in the US. Are others invested in both companies?
2 · Reply
Kashking03
Kashking03 Dec. 22 at 1:27 AM
$OCUL $XBI #Biotechs BofA sees small- and mid-cap biotech well positioned into 2026 • Top picks: $ARGX Argenx • $KALV KalVista Pharmaceuticals • $OCUL Ocular Therapeutix
0 · Reply
Fairvalue10
Fairvalue10 Dec. 21 at 9:29 AM
$OCUL Honestly, if nothing happens before SOL-1, then publishing these 8-Ks makes absolutely no sense. If they are not tied to a transaction that precedes the readout, why would you create a legally binding disclosure that could be used against you in court? If SOL-1 turns out not to be sufficient, the stock collapses and you face class actions for misleading statements. It is precisely this major step that makes me believe a transaction is underway. The path to NDA is laid out to justify a significant premium, with two CVRs, one tied to SOL-1 and another to FDA approval. Without advanced and imminent discussions, you would simply issue an IR press release on the FDA path, enter a quiet period without any 8-K (as that goes without saying), and then release the results on the chosen date
4 · Reply
orphaschwiesow
orphaschwiesow Dec. 21 at 6:38 AM
Biotech Outlook 2026 | Bank of America • BofA sees small- and mid-cap biotech well positioned into 2026 • Top picks: $ARGX Argenx • $KALV KalVista Pharmaceuticals • $OCUL Ocular Therapeutix • $VRTX Vertex Pharmaceuticals • Key drivers: clearer regulatory pathways, improved commercial execution, and a dense slate of upcoming clinical data
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 20 at 3:13 PM
Enter: $OCUL Calls Strike Price: $14 Expiry Date: JAN 16 2026 Buy in Price: $0.80 - $0.85 Sell Price: $1.34 Profit : +68% (Turn every $1 into $1.68) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
FullPorrtDipz
FullPorrtDipz Dec. 20 at 12:37 PM
0 · Reply
Fairvalue10
Fairvalue10 Dec. 20 at 8:30 AM
$OCUL Do you really believe a company would file an 8-K stating that SOL-1 alone is sufficient for the NDA pathway if there were any chance that AXPAXLI were « dead on arrival » ? Do your due diligence, you clearly haven’t understood what this means. This 8-K is legally binding. It is precisely a way of saying, between the lines, that the efficacy of AXPAXLI is so strong and so compelling that management is willing to commit to it in a legally binding manner.
2 · Reply